INTRODUCTION
Phase I oncology clinical trials are typically first-in-human studies characterized by a small number of patients with a goal of determining the maximum tolerated dose of an experimental drug. The maximum tolerated dose is defined as the highest dose at which the probability of dose-limiting toxicity (DLT) is no more than, or close to, a prespecified target response rate p T (eg, p T = 0.3). Numerous dose-finding designs have been developed, such as the 3 + 3 design, 1 the continual reassessment method, 2 and the modified toxicity probability interval (mTPI; mTPI-2) methods, [3] [4] [5] as recently reviewed by Sverdlov et al. 6 Most of the dose-finding trials consider DLT within the first cycle of treatment as the primary outcome and do not allow multicycle intrapatient dose modification. In recent drug development and patient care efforts, it has become more common to consider a regimen that involves multiple drugs over multiple cycles. For example, a new developmental drug may be considered as an additional treatment in chemotherapy that includes other standard drugs over multiple cycles.
Our work was motivated by and applied to such a trial at The University of Chicago for a rare form of leukemia. In this trial, a Janus kinase inhibitor, ruxolitinib, was added to a threecycle US Food and Drug Administration (FDA)-approved chemotherapy backbone that includes cycle-specific drugs (Table 1) . Although the dose of chemotherapy is fixed at the FDA-approved level, the investigational drug was administered at varying doses for each patient across cycles. Therefore, intrapatient dose modifications were required over three cycles to protect patient safety and learn the toxicity profile of different dose sequences. In other words, the trial could be considered as a single-agent multicycle Purpose Statistical designs for traditional phase I dose-finding trials consider doselimiting toxicity in the first cycle of treatment. In reality, patients often go through multiple cycles of treatment and may experience toxicity events in more than one cycle. Therefore, it is desirable to identify the maximum tolerated sequence of three doses across three cycles of treatment.
Methods Motivated by a three-cycle dose-finding clinical trial for a rare cancer with a JAK inhibitor, we proposed and implemented a simple Bayesian adaptive dose-cycle finding (BaSyc) design that allows intercycle and intrapatient dose modification. Because of the patient-specific dosing strategy over cycles, the BaSyc design is suited as a method in precision oncology.
Results BaSyc is simple and transparent because its algorithm can be summarized as two tabulated decision rules before the trial starts, allowing physicians to visually examine these rules. In addition, BaSyc employs a time-saving enrollment scheme that speeds up the trial. Extensive simulation studies show that BaSyc has desirable operating characteristics in identifying the maximum tolerated sequence.
Conclusion
The BaSyc design provides a first-of-kind multicycle approach for dose finding and will likely lead to better and safer patient care and drug development. dose-finding study, which aimed to identify the maximum tolerated sequence (MTS) of ruxolitinib dose levels across three cycles. The MTS is defined as the highest sequence of three doses at which the probability of toxicity per cycle (TPC) is no more than or close to a prespecified target response rate p T , given that the probability of toxicity at each cycle is also no more than or close to p T . The probability of TPC of a sequence is defined as the average of three cycle-specific toxicity probabilities at the three dose levels of the sequence. Sequence A is higher than sequence B if the sum of the three dose levels of A is larger than the sum of B. Because of the low prevalence of the disease, the study sample size was small, up to 15 patients. Three doses of ruxolitinib were considered for each of the three cycles; therefore, there were a total of 27 possible dose-cycle combinations for three cycles of treatment.
The complication of the trial was the intrapatient dose modifications over cycles. A formal statistical inference would involve a dose-cycleresponse model and optimal sequential decision making for each patient. Such approaches usually work well when the sample size of the trial is sufficiently large, as seen in the dynamic treatment regimen methods, 8 reinforcement learning, 9 and sequential multiple assignment randomized trials. 10 These approaches aim to better reflect the intrinsically multistage, adaptive structure of medical decisions, in both trial design and analysis of the trial data. However, they are not tailored to optimize patient doses over multiple cycles in a small dose-finding trial. Some works in the literature have investigated multiple-cycle treatment strategies, most of which have not considered intrapatient dose modification. [11] [12] [13] [14] [15] [16] There are two exceptions. The first is Lee et al, 17 who proposed an innovative phase I/II design to adaptively and dynamically optimize a patient's dose in each of two cycles of therapy based on the joint binary cycle-specific efficacy and toxicity outcomes. Although this method allows intrapatient dose modification, it is only compatible with two cycles, requires relatively large sample sizes, and is complicated and difficult to implement. The second exception is Fernandes et al, 18 who developed an approach to model DLT in multiple treatment cycles based on Markov chains. However, this design is tailored for a specific trial setting and is difficult to generalize to trials in different settings.
BAYESIAN ADAPTIVE DOSE-CYCLE FINDING Overview
The Bayesian adaptive dose-cycle finding (BaSyc) design consists of decisions to determine the appropriate dose in each cycle for enrolled patients and to select the MTS once the trial is completed. Patients are usually enrolled in cohorts, (eg, three patients per cohort). If a cohort of patients is either just entering the trial or completes treatment in a cycle, the BaSyc design applies two decision rules to the cohort: 1) the dose continuation rule (DCR) that determines whether the cohort should receive treatment in the next cycle for additional treatment 2 ascopubs.org/journal/po JCO™ Precision Oncology (unless the cohort has completed all three cycles), and 2) the dose allocation rule (DAR) that decides the dose level of the next cycle if the DCR allows the patients to continue to the next cycle. The DCR and DAR are continuously applied to patients who are actively receiving treatment in any cycle of the treatment. At the end of the trial, BaSyc estimates the MTS based on a model-based inference accounting for the order of the dose sequences. Figure 1 illustrates the general scheme of the BaSyc design for the motivating trial with three doses and three cycles of treatment.
DCR and DAR
The basic concept of the DCR is that if the probability of toxicity of the lowest dose in the next cycle is considered lower than the target rate p T , the cohort can move to the next cycle for additional treatment (ie, the decision is a go). This is because the cohort can always be treated at the lowest dose in the next cycle if the DCR is satisfied. Here, we assumed that there are intercycle washouts and palliative care that allow patients to recover from potential adverse effects from previous treatment. Technical details of the DCR are given in the Appendix.
If the DCR is a go for a cohort, the cohort will enter the next cycle for additional treatment. Then the DAR decides the dose level of the next cycle. There are three cases where the DAR is applied. First, the DAR always assigns the first cohort patients at the lowest dose level in all the cycles of treatment, which is a default rule to ensure the safety of the lowest dose in all three cycles. Second, for a newly enrolled cohort, the DAR decides the dose level for the cohort in the first cycle, labeled DAR-1. In this case, DAR-1 follows the same decision rule as in the mTPI-2 design. 5 Specifically, the dose level is decided based on the observed toxicity data from previously enrolled patients treated at the most recent dose in the first cycle. Given the observed data, the mTPI-2 design will decide the dose for the newly enrolled cohort. Third, the DAR is needed 
DAR-2a.
For the subcohort of patients without DLTs observed in the existing cycle, DAR-2a decides a dose based on the integration of the toxicity data of the cohort in the existing cycle and the toxicity data of the previously enrolled cohort that has already been treated in the next cycle.
DAR-2b.
For the subcohort of patients with DLTs, DAR-2b assigns a lower dose in the next cycle that is deemed acceptable. This ad hoc rule is needed to protect patient safety.
The two subcohorts undergo the DCR and DAR separately hereafter until all three cycles of treatment are completed or until they exit the trial. Technical details are given in the Appendix.
Given the observed toxicity data, all the DCR and DAR decisions can be enumerated and summarized into tabular format. Figure 2 shows an example. In the first table, the DCR is summarized as go/no-go decisions. This table is applied to the lowest dose of the next cycle at which the current cohort would be treated. The second table provides the decisions based on the DAR. Motivated by the mTPI-2 design, 5 dose allocation is presented in the form of dose escalation, stay, or de-escalation to give the candidate dose level at the next cycle relevant to the dose level of the cycle we currently consider. This table is applied to the dose at which the current cohort is treated and the dose at which the previous cohort is most recently treated in the next cycle. Therefore, it might be used multiple times for the DAR. The two tables can be generated and predetermined before the trial starts for examination by physicians.
In the DAR, we used the mTPI-2 design as the backbone for decision making. To apply the decision rules of mTPI-2, we needed to provide the p T value and an equivalence interval (EI) in the form of (p T − ε 1 , p T + ε 2 ). Here, the EI specifies the range of toxicity probabilities that is considered close to the target probability p T by the mTPI-2 design. The default values of ε 1 and ε 2 are 0.05.
Dose-Finding Algorithm
To begin a trial, the BaSyc design treats the first cohort of patients at the lowest dose level in all three cycles. Then, after the toxicity outcomes from the first cycle are observed, the DCR decides whether the cohort will go to the next cycle, and the DAR decides which dose level to use if the DCR decision is go. Also, a new cohort is open for enrollment at this point at the first cycle as the current cohort moves onto the next cycle or exits the trial. BaSyc determines a dose level based on the DAR in the first cycle for this newly enrolled cohort of patients. This process is repeated until all cohorts finish all cycles of treatment unless the trial is terminated early because of excessive toxicity (safety rules are given in the Appendix). As a default rule, the cohort at a given cycle must wait for the cohort at the next cycle to complete follow-up before it can enter the next cycle.
We demonstrate in Table 2 how the BaSyc design guides the motivating dose-cycle trial with three doses and three cycles. In this trial, each cycle lasted 8 weeks consisting of a 4-week treatment followed by 4-week washout and recovery. A walk-through of the table is provided in the Appendix. For safety, the BaSyc design applied additional safety rules 3, 19 throughout the entire trial. Details are provided in the Appendix.
Cohort Enrollment
It is worth noting that the BaSyc design uses a fast cohort enrollment scheme. Specifically, once the current cohort completes the first cycle of treatment with observed outcome data, the next cohort can be enrolled and assigned a dose level in the first cycle. The current cohort will either exit the trial or move to the next cycle. For example, in Table 2 , in week 24, after cohort 3 completed the first-cycle treatment at dose level 2, the next cohort (cohort 4) was enrolled and treated at dose level 1 as its first-cycle therapy. Cohort 3 would continue to the next cycle for additional treatment. This enrollment scheme is important to speed up the trial with a small sample size targeting a rare disease.
MTS Selection
At the end of the trial, among all the candidate sequences of dose-cycle combinations, a sequence of three doses for three cycles would be selected as the MTS. We develop a method based on the isotonic transformation 20 of the estimated probability of TPC for each sequence to determine the MTS. Technical details are provided in the Appendix.
SIMULATION STUDIES Simulation Setup
We evaluate the reliability (MTS recommendation) and safety of the BaSyc design using computer-simulated trials based on the setting of the motivating trial. There are three prespecified doses and three cycles. The maximum sample size is 15, and patients are enrolled in cohorts of three. The MTS target toxicity probability is 
Fig 2.
Two decision tables of the Bayesian adaptive dose-cycle finding (BaSyc) design for the motivation trial. The sample size was 15, target toxicity probability p T = 0.3, and equivalence margins ε 1 = ε 2 = 0.05. Each column number represents the number of patients treated, and each row number represents the number of patients experiencing toxicity, at a given dose where the decision is applied. (A) Go (G)/no-go (NG) decisions according to the dose continuous rule (DCR), in which the letters in blue and red represent G and NG decisions, respectively. This table is applied to the lowest dose of the next cycle at which the current cohort might be treated. For example, if the current cohort has completed treatment in cycle 1, the table is applied to dose level 1 in cycle 2. (B) Dose allocation decisions according to the dose allocation rule (DAR), in which the letters in blue, gold, green, and red represent dose escalation (E), staying at the current dose (S), dose de-escalation (D), and dose de-escalation and exclusion (DU) because of toxicity, respectively. This table is applied to the dose at which the current cohort is treated and the dose at which the previous cohort is treated in the next cycle. p T = 0.3, and the choices of ε 1 and ε 2 are both 0.05. The probability threshold for the additional safety rules is ξ = 0.95. We investigate six different scenarios in the simulation studies, as summarized in Table 3 . We provided the true toxicity probabilities of the three dose levels in the first cycle and assumed that the toxicity probability would increase by 10% per cycle at the same dose level. For example, in scenario 1, the probability of toxicity for dose level 1 in cycle 1 is equal to 0.15. Then, in cycles 2 and 3, the true probability is assumed to increase to 0.165 and 0.1815, respectively. For each scenario, 10,000 simulated trials are conducted on computer.
Operating Characteristics
The simulation results for scenarios 1 to 6 are summarized in Table 3 , with four sections per scenario. Section 1 lists the true toxicity probabilities of three prespecified dose levels in the first cycle and the target toxicity probability p T . Sections 2 to 5 represent four different criteria that summarize the performance of the BaSyc design. Section 2 presents the frequency of MTS selection. The higher the frequency, the better the performance. Recall that the MTS is defined as the highest sequence of three safe doses with the true probability of TPC (calculated as the average of the three true toxicity probabilities corresponding to the three dose levels) closest to p T and falling in the EI (p T − ε 1 , p T + ε 2 ). If a scenario has no dose sequence falling in the EI, the highest sequence of three safe doses with the true probability of TPC less than p T is considered the true MTS. Here, a safe dose is a dose with toxicity probability less than (p T + ε 2 ). In our simulation, EI = (0.25, 0.35), and we highlight the true MTS with bold face. Section 3 provides the average number of toxicities and patients treated at each dose cycle. A desirable design should allocate most patients at doses with a probability of toxicity below p T . Section 4 presents the percentage of patients treated above the MTS, and we would want to see a small value. Section 5 provides the percentage of early termination according to rule 1. This percentage should be high if the lowest sequence is overly toxic. The BaSyc design performs well, exhibiting a strong safety profile and desirable power in selecting the MTS. Simulation results for a larger sample size are summarized in Table 4 . Details of the results and a sensitivity analysis of the sample size are provided in the Appendix.
DISCUSSION
We propose the BaSyc design to fulfill the need for statistical designs for multiple-cycle dose-finding trials that allow for intrapatient modification. No practical methods are available, and the two existing designs 17, 18 in the literature are either highly complex or tailored for specific trials.
Perhaps the most attractive feature of the BaSyc design is its simplicity and transparency, as shown in Figure 2 . In addition, the performance of the BaSyc design is promising. In particular, the BaSyc design exhibits strong safety, because it tends to assign patients to the doses with safe toxicity rates. Appendix Table A1 summarizes the dose allocation decisions for the BaSyc design across 10,000 simulated trials. We can see that escalation and de-escalation will never happen if the true toxicity probability of a dose is located in the higher interval (p T + ε 2 , 1) and the lower interval (0, p T + ε 1 ), respectively.
In this report, we implemented BaSyc for a realworld trial with three dose levels for three cycles of treatment. This trial is pending after receiving approval for the investigational new drug application by the FDA for review. The BaSyc design can be easily applied to different numbers of doses and cycles with almost no modification. However, in practice, having many doses will quickly lead to an unmanageable number of possible dose-cycle combinations. For example, a total of 5 3 = 125 sequences are available for trials with five dose levels and three cycles.
BaSyc uses independent beta/binomial models as the working model to estimate the toxicity probability of each dose in each cycle based on all patients' data at that dose/cycle. This naïve construction leads to simplicity and transparency. Alternatively, one could consider a dependent model, such as the Markov model in Fernandes et al, 18 to estimate the toxicity probabilities.
In BaSyc, we focused on the dose-cycle trials with binary outcomes. Because BaSyc is a hybrid of a model-free algorithm and a model-based method, our proposed design can be extended to ordinal outcomes. The dose-finding methods that account for toxicity categorized according to their severity 21,22 could replace mTPI-2, which is used for the DCR and DAR in BaSyc.
Regarding the sample size of the trial, Ji et al NOTE. Bold font indicates the true maximum tolerated sequence for each scenario. A total of 10,000 trials were simulated for each scenario. The true toxicity probabilities of three prespecified dose levels in the first cycle are presented for each scenario. The toxicity probability increases by 10% per cycle at the same dose level. Probability of toxicity per cycle is the average of the toxicity probabilities of the three doses in the sequence. Abbreviations: DLT, dose-limiting toxicity; MTS, the highest sequence of three doses at which the probability of toxicity per cycle is no more than or close to a pre-specified target response rate p T , given that the probability of toxicity at each cycle is also no more than or close to NOTE. Bold font indicates the true maximum tolerated sequence for each scenario. A total of 10,000 trials are simulated for each scenario. The true toxicity probabilities of three prespecified dose levels in the first cycle are listed are presented for each scenario. The toxicity probability increases by 10% per cycle at the same dose level. Probability of toxicity per cycle is the average of the toxicity probabilities of the three doses in the sequence. Abbreviations: DLT, dose-limiting toxicity; MTS, the highest sequence of three doses at which the probability of toxicity per cycle is no more than or close to a pre-specified target response rate p T , given that the probability of toxicity at each cycle is also no more than or close to 
Notation
Suppose under consideration is a total of I candidate dose levels and J treatment cycles, indexed by i = 1,2,…,I; j = 1,2,…,J. Denote p ij the unknown probability of toxicity associated with the i-th dose in j-th cycle. The toxicity is assumed to be monotonic increasing with the dose level: p 1j ≤ p 2j ≤ ... ≤ p Ij , for j = 1,2,…,J. Let x ij and n ij be the number of toxicity events and total patients treated at dose i in cycle j, respectively. Let k index the cohort, k = 1,2,…,K, where K is the maximum number of cohorts that will be recruited to the trial.
During dose-cycle finding (not for maximum tolerated sequence [MTS] selection), we use simple and independent beta priors across doses and cycles and an independent binomial likelihood as a working model for the estimation of p ij . This inference is conducted to guide dose-cycle finding during the course of patient enrollment and assignment. The application in Bayesian adaptive dose-cycle finding (BaSyc) is detailed here.
Dose Continuation Rule
For cohort k that has been treated at dose i in cycle j, the dose continuation rule (DCR) for cohort continuation (whether the cohort can continue treatment at cycle (j + 1)) is described as follows:
• If cohort k has finished the last cycle of therapy (ie, j = J), cohort k exits the trial.
• If cohort k has not finished all cycles of therapy (ie, j < J), and if Pr{p 1,j +1 > p T |data} > ξ, where ξ is a prespecified cutoff probability and often set to be close to 1 (eg, ξ = 0.95), stop cohort k for any additional treatment, and patients in cohort k exit the trial.
• Otherwise, continue this cohort k to the next cycle (j + 1).
This algorithm states that when the probability that toxicity of the lowest dose level (dose level 1) in cycle (j + 1) is higher than the target p T does not exceed a large value, cohort continuation is allowed. The posterior probability Pr{p 1,j +1 > p T |data} is calculated based on a simple beta/binomial model. Let x 1,j+ 1 and n 1,j+ 1 be the cumulative number of patients (across all the previous and current cohorts) with dose-limiting toxicity (DLT) events and treated at dose level 1 at cycle (j + 1), respectively. Then assume x 1,j+ 1 | n 1,j+ 1 ~ Binomial(n 1,j+ 1 , p 1,j+ 1 ), p 1,j+ 1 ~ Beta (1, 1) and the posterior distribution p 1,j+ 1 | data ~ Beta(1 + x 1,j+ 1 , 1 + n 1,j+ 1 − x 1,j+ 1 ). This beta distribution is used to calculate the posterior probability.
Dose Allocation Rule
If cohort k in cycle j can proceed to the next cycle, the dose assigned to the next cycle (j + 1) is dependent on the cumulative data from both the current cycle j and the next cycle (j + 1). We consider three subrules, denoted as dose allocation rule 1 (DAR-1), DAR-2a, and DAR-2b. Details are as follows.
• As a safety and default rule, the patients in the first cohort (ie, k = 1) are always treated at the lowest dose (i = 1) in all J cycles.
• DAR-1: For a newly enrolled cohort (except the first cohort), DAR-1 provides the dose level in the first cycle and follows the same decision from the modified toxicity probability interval 2 (mTPI-2) design. 5 That is, the dose level is decided based on the toxicity data from the current dose used to treat patients in the first cycle. Such data accumulate all the toxicity outcomes from previously treated cohorts at this dose.
Then, consider a cohort of patients that has just completed treatment in the first cycle at a dose level. Suppose the cohort will move to the second cycle for additional treatment. Note that some patients in the cohort might experience DLT outcomes in the first cycle, and the others might not. As a personalized strategy and to protect patient safety, we split the cohort into two subcohorts: the patients with DLTs and those without. The dose allocation decisions are made separately for these two subcohorts, using the following DAR-2a and DAR-2b rules:
• DAR-2a: For the subcohort of patients without DLTs after the first cycle treatment, the dose level of the second cycle for this (sub)cohort depends on two types of data: 1) the toxicity data (data 1 ) at the dose (dose 1 ) in cycle 1 where the cohort has been treated, and 2) the toxicity data (data 2 ) at the dose (dose 2 ) in cycle 2 where the previous cohort has been treated. Here, the previous cohort refers to the cohort of patients enrolled just before the current cohort, and the toxicity data or the data (also hereinafter) refer to the data from all enrolled patients treated at the corresponding dose. DAR-2a applies the mTPI-2 design 5 to decide the dose level in cycle 2. Specifically, given data 1 and dose 1 , the mTPI-2 design will output a candidate dose level i 1 , and given data 2 and dose 2 , mTPI-2 will output another candidate dose i 2 . Then DAR-2a selects the dose i = min{i 1 ,i 2 }, the minimum of i 1 and i 2 , as the final dose for treating the (sub)cohort in cycle 2.
• DAR-2b: For the second subcohort of patients with DLTs, de-escalate to a lower dose in the second cycle as follows. If the current dose is the lowest dose, we still stay at the same dose; otherwise, decrement by one level. Specifically, given the dose (dose 1 ) in cycle 1 and the candidate dose i 2 that mTPI-2 gives based on data 2 and dose 2 from cycle 2, DAR-2b selects the dose i = min{max{dose 1 − 1,1},i 2 }, the minimum of the dose 1 level lower than the current dose in cycle 1, and i 2 as the final dose for treating the cohort in cycle 2.
Note that because of the cohort split, the previously enrolled subcohorts may have been treated in cycle 2 at two dose levels, say dose 21 and dose 22 . The outcome data from both subcohorts, denoted as data 21 and data 22 , will be used to inform the cycle 2 dose for the subsequent cohort that will start from the first cycle. In particular, for each of the data 21 and data 22 , the mTPI-2 design will give two candidate doses i′ 21 and i′ 22 as the potential dose for the subsequent cohort in cycle 2. Then, the minimum of i′ 21 and i′ 22 will be provided as the candidate dose, denoted as i 2 = min{i′ 21 ,i′ 22 }, for the subsequent cohort as the cycle 2 candidate dose. The two subcohorts will undergo the DCR and DAR separately hereafter until they either complete all three cycles of treatment or exit the trial. The same principle is applied to decide the dose level in cycle 3 if needed. Table 2 summarizes how the BaSyc design guides the motivating dose-cycle trial with three doses and three cycles. In this trial, each cycle lasts 8 weeks, consisting of a 4-week treatment followed by 4-week washout and recovery. We walk through the first few cohorts in Table 2 . First, according to the default safety rule, cohort 1 is treated at dose 1 (D1) in all three cycles. Therefore, at week 0 (not shown), cohort 1 is enrolled and assigned to D1. At week 8, cohort 1 completes treatment at D1 with 0 toxicity outcome (0 DLT of three patients). The DCR decision is to go to cycle 2. At this point, cohort 2 is enrolled and assigned to the next higher dose, dose 2 (D2), according to the DAR decision, because cohort 1 has not exhibited any toxicity. At week 16, cohort 1 completes treatment at D1 in cycle 2 with 0 toxicity outcome, and cohort 2 completes treatment at D2 in cycle 1 with 1 DLT outcome. For cohort 1, the DCR decision is to go to cycle 3 and to be treated at D1 (again as the default rule). For cohort 2, the DCR decision is to go to cycle 2, because the lowest dose in cycle 2 is considered safe. Cohort 2 is then split into two subcohorts according to the DAR. The single patient with DLT, patient 4, is de-escalated to D1, and the remaining two patients without DLTs, patients 5 and 6, stay at D2. Also, at week 16, cohort 3 is enrolled in the first cycle and treated at D2 according to the DAR. D2 is selected for cohort 3 because the three patients in cohort 2 exhibited one DLT event when treated at D2. Therefore, the DAR decides to continuously treat cohort 3 at the same dose, D2. This process continues for subsequent cohorts and cycles at weeks 24, 32, and so on, until all 15 patients (or five cohorts) have completed treatment at week 56.
Walkthrough of the Hypothetic Trial

Safety Rule Applied in BaSyc
For safety, the BaSyc design applies two additional safety rules throughout the entire trial:
• Rule 1 (early termination): For any cycle, if the toxicity probability of the lowest dose is higher than the target p T with a large probability-that is, if ∃j*∈{1,2,…,J} such that Pr{p 1j* > p T |data} > ξ, where ξ is close to 1 (say = ξ = 0.95)-terminate the trial early.
• Rule 2 (dose exclusion): If the toxicity probability of dose i in cycle j is higher than the target p T with a large probability, Pr{p ij > p T |data} > ξ, exclude doses i and the higher doses from cycle j and higher cycles-that is, doses {i,i + 1,…,I} will never be used in the trial in cycles {j,j + 1,…,J} again.
The posterior probabilities in both rules are calculated based on the simple beta/binomial calculation proposed in the mTPI design. 3 Details are provided in Appendix under Dose Continuation Rule.
MTS Definition and Selection
After the enrollment and dose-cycle finding are completed, in the MTS selection, we use a frequentist and nonparametric probability model to make inference. Specifically, we essentially want to estimate the toxicity per cycle (TPC) q s , which is the average of the three toxicities of the doses in a sequence s (described under Definition of MTS). We then construct an unbiased estimate of TPC q̃s (described under Estimation of q̃s) and order-transform them based on isotonic regression (described under MTS Selection). Lastly, we select the MTSs in which the isotonically transformed q̃s are closest to p T among all the cycles.
Definition of MTS.
In the motivation trial, there are three doses and three cycles, which amounts to a total of S = 27 sequences of dose cycles. p dsj,j /3 be the average probability of toxicity of the sequence across three cycles (ie, the probability of TPC). Then, the MTS is the highest sequence whose q s is closest to p T . Also, for additional safety, we require that p dsj,j in the MTS for each cycle j must be no higher than p T as well.
Estimation of q s .
First, we select MTS among sequences that have been used in the trial and are not unacceptable. A sequence s is unacceptable if the toxicity probability of each dose in each cycle is higher than p T with a large probability, defined as ∃ j = 1,2,3, Pr{p dsj,j > p T |Data} > ξ, where d sj denotes dose levels {1,2,3} and ξ is close to 1, say ξ = 0.95. The posterior probability Pr{p dsj,j > p T |Data} is based on a simple beta/binomial hierarchic model, similar to the calculation under Dose Continuation Rule.
Among all the safe sequences that satisfy the condition above, we want to select the highest sequence with overall q s close to p T , subject to the toxicity probability of the same dose level nondecreasing across cycles. Suppose Data = {(x sj ,n sj ), s = 1,2,…,S, j = 1,2,3} and denote x sj the number of patients with DLTs among the total number of patients n sj treated at dose d sj in cycle j of sequence s. An unbiased estimate of q s is the average toxicity rate defined as q̃s = ∑ j=1 3 x sj / ∑ j=1 3 n sj .
It is obvious that E(q̃s) = q s when n sj is the same across cycles j. Recall n sj is the number of patients completing all three cycles of treatment after the dose sequence s. So n sj is equal across cycles for a sequence. Therefore, we use q̃s as an unbiased estimator to estimate q s .
MTS selection.
One could select the sequence that has the smallest value of |q̃s − p T |. However, the problem with that approach is that because of random chance, a sequence with a higher order (and therefore higher toxicity) might have a smaller q̃s than a lower-ordered sequence. For example, it is possible that the toxicity data for sequence 1,1,1 include only one toxicity event in all three cycles, whereas the data for sequence 2,1,1 include no toxicity event. Then, if n sj = 3, the q̃s value for sequence 1,1,1 is 1/9 and 0 for sequence 2,1,1. However, sequence 2,1,1 is in theory a more toxic sequence, because it uses dose level 2 in cycle 2 instead of dose level 1. Therefore, selecting the sequence based on the distance of |q̃s − p T | is not valid, because we would select 1,1,1 as the MTS, not 2,1,1 in this case.
To address this issue, we propose an isotonic transformation and calculate transformed q̃s values using the pool adjacent violator algorithm (PAVA) 20 just like in the mTPI design 3,4 and mTPI-2 design. 5 Here, we still use the sequence-specific data for the isotonic transformation. However, the sequences are partially ordered with ties, and therefore, PAVA cannot be directly applied, because it requires simple ordering of the sequences. For example, sequences 1,2,1, and 2,1,1 have the same order because both of their d s * values equal 4. To solve this issue, we propose a simple solution. When there is a tie between m sequences, there are m! possible simple orderings among them. Then, assuming with probability 1/m! that one of the orderings, say ordering w, is true, we apply PAVA to the following ordering w of q̃s, w = 1,2,…,m!. We obtain q̂s w as the PAVA-transformed value of q̃s given the w-th simple ordering. We then select the dose sequence with the smallest difference |q̂s w − p T | as the estimated MTS for the w-th simple ordering. Let us denote the estimated MTS D w . Then out of all the m! possible simple orderings, we obtain m! estimated MTS, denoted as {D 1 ,D 2 ,…,D m! }. It is likely that these D m! MTSs also have ties, because the same sequence can be selected under different simple orderings. Therefore, let {D 1 *,D 2 *,…,D* L } (L ≤ m!) be the unique sequences that are selected as the estimated MTS, and let {f 1 ,f 2 ,…,f L } be the corresponding frequencies of selection, with f 1 being the number of times sequence l is selected as the estimate MTS, l = 1,2,…,L. Then, finally, the sequence D l* * that has nonincreasing dose levels across three cycles and the largest frequency f l* is selected as the estimated MTS. We require that the dose levels of MTS are nonincreasing because of the assumption that the toxicity rate of the same dose increases over cycles. Therefore, the dose levels of the MTS cannot be increasing, or else the lower dose in the early cycle can always be replaced by the higher dose in the later cycle. When there are ties between f l* for multiple sequences, select the sequence with the lowest order as a conservative choice. If the orders are tied, then select the sequence with the lowest dose in the first cycle, the lowest dose in the second cycle if first-cycle dose is tied, or the lowest dose in the third cycle if first-and second-cycle doses are tied.
Simulation Results
Main results.
In scenario 1, sequence 1,1,1 is selected with the highest frequency (24.2%), and sequences 2,1,1 and 2,2,1 come in second and third, with a frequency of 19.7% and 19.0%, respectively. Sequence 2,2,1 is the true MTS. Sequence 2,2,1 is not selected with the highest frequency because of a small sample size (n = 15) and because the first dose has a nontrivial toxicity probability (0.15). This makes it difficult to escalate to dose 2 quickly. As summarized in Table 4 , with a larger sample size (n = 30), sequence 2,2,1 gets selected the most frequently. Most patients are treated at doses with toxicity probabilities smaller than p T . Because dose level 3 is overly toxic, few patients are allocated to it at any cycle. These results show that BaSyc is strong in protecting patient safety.
Scenario 2 presents a similar pattern of dose-toxicity relationship to scenario 1, except that the toxicity probability of dose level 2 is now below p T = 30%. The true MTS is 2,2,2, which is only selected 14.8% of the time with the fourth frequency. The same reason as scenario 1 is held.
Scenario 3 assumes that all the dose levels are safe with toxicity probabilities below p T . With merely 15 patients, the BaSyc design is able to escalate quickly and select the sequence 3,3,2 and true MTS 3,3,3 with the highest and second highest probability of 20.9% and 20.4%, respectively. This suggests that the BaSyc design is nimble and can reach high dose-cycle combinations even with small sample sizes. Scenario 4 presents an opposite case to scenario 3, because all the doses are overly toxic with toxicity probabilities above p T . We can see that 99.21% of the simulated trials are terminated early without selecting any dose sequences as the MTS. On average, approximately eight patients are treated in the trial at low doses. This scenario demonstrates the ability of the BaSyc design to stop the trial quickly in case of excessive toxicity in all dose sequences. Scenarios 5 and 6 reflect situations where there is a leap in toxicity probabilities across the three doses. In scenario 5, the leap lies between doses 2 and 3, with the first two doses below p T . Therefore, the true MTS is 2,2,2. In scenario 6, the jump locates between doses 1 and 2, with 1,1,1 being the true MTS. The selection frequency of the true MTS is 39.7% for scenario 5 and 45.0% for scenario 6. In both scenarios, the MTS receives the most patients on average, whereas overly toxic doses receive much fewer patients. In scenario 6, 21.4% of patients (approximately three patients) are treated above the MTS because of the high probability of toxicity of the second dose level 0.46.
Sensitivity to sample size.
To evaluate the effect of sample size on the performance of BaSyc, we implement the BaSyc design for the same scenarios with a larger sample size of 30. Results are listed in Table 4 . Across the scenarios, we see an increase of power in selecting the true MTS. The safety of the BaSyc design is again highlighted. For example, in scenario 4, toxic doses are assigned with a small number of patients, and trials are terminated early.
ascopubs.org/journal/po JCO™ Precision Oncology 19 NOTE. The true toxicity probabilities of three prespecified dose levels in the first cycle are 0.15, 0.3, and 0.45 (scenario 1). The target toxicity probability p T = 0.3, and the choices of ε 1 and ε 2 are both 0.05. Symbol y denotes the number of dose-limiting toxicities, and n denotes the number of patients treated. Abbreviation: BaSyc, Bayesian adaptive dose-cycle finding.
